Fig. 7

Graphical abstract illustrating the proposed mechanism of RV combined with CFZ in patients with MM. (A) Graphical representation of the proposed mechanism showing how proteasome inhibition (CFZ) increases the viral delivery to MM cells and enhances myeloma oncolytic reovirus therapy by suppressing IFN-I monocytic anti-viral immune responses through monocyte expansion and CD8+ cytotoxic T cell activation against cancer cells; (B) Graphical representation of the proposed mechanism of the lack of viral delivery to MM cells in the absence of proteasome inhibition